SCHEMBL18530804

SCHEMBL18530804

Cc1c(Cl)nc(Cl)c2cccnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
NPC1 O15118 1/20 0.55
CCR1 P32246 4/20 0.46
CCR8 P51685 4/20 0.46
ALDH1A1 P00352 3/20 0.44
LMNA P02545 6/20 0.42
KDM4E B2RXH2 5/20 0.42
MAPT P10636 5/20 0.42
HTT P42858 4/20 0.42
METAP1 P53582 3/20 0.42
SLC6A2 P23975 3/20 0.42
METAP2 P50579 2/20 0.42
BRD4 O60885 1/20 0.42
PSMD14 O00487 1/20 0.42
COPS5 Q92905 1/20 0.42
TP53 P04637 3/20 0.41
CYP3A4 P08684 3/20 0.41
ALOX15 P16050 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530814 0.81 HSP90AA1 (0.47) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL18260476 0.77 L3MBTL1 (0.46) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL21297755 0.77 HSP90AA1 (0.73) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL12747793 0.77 HSP90AA1 (0.53) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL14212958 0.73 KDM4E (0.62) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL30454561 0.73 HSP90AA1 (0.50) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL15624642 0.73 L3MBTL1 (0.82) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL250356 0.72 L3MBTL1 (1.00) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL22250697 0.72 HSP90AA1 (0.59) HSP90AA1L3MBTL1NPC1CCR1CCR8
SCHEMBL7435562 0.72 PRMT5 (0.46) HSP90AA1L3MBTL1NPC1CCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200101068-A1 Heteroaryl Derivatives as PARP Inhibitors LUPIN LIMITED (IN) 2020-04-02 US disclosed
US-20200101068-A1 Heteroaryl Derivatives as PARP Inhibitors LUPIN LIMITED (IN) 2020-04-02 US disclosed
EP-3337802-A1 HETEROARYL DERIVATIVES AS PARP INHIBITORS Lupin Limited (IN) 2018-06-27 EP disclosed
WO-2017029601-A1 HETEROARYL DERIVATIVES AS PARP INHIBITORS LUPIN LIMITED (IN) 2017-02-23 WO disclosed
WO-2017029601-A1 HETEROARYL DERIVATIVES AS PARP INHIBITORS LUPIN LIMITED (IN) 2017-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200101068-A1 Heteroaryl Derivatives as PARP Inhibitors PARP1, PARP2, PARP3 HSP90AA1 3646/4885L3MBTL1 1695/4885NPC1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.